These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25487273)

  • 21. Waive CRISPR patents to meet food needs in low-income countries.
    van der Oost J; Fresco LO
    Nature; 2021 Sep; 597(7875):178. PubMed ID: 34489579
    [No Abstract]   [Full Text] [Related]  

  • 22. Who owns CRISPR-Cas9 in Europe?
    Kupecz A
    Nat Biotechnol; 2014 Dec; 32(12):1194-6. PubMed ID: 25489834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Visualization analysis of CRISPR/Cas9 gene editing technology studies.
    Du QS; Cui J; Zhang CJ; He K
    J Zhejiang Univ Sci B; 2016 Oct.; 17(10):798-806. PubMed ID: 27704749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted genome editing in the rare actinomycete Actinoplanes sp. SE50/110 by using the CRISPR/Cas9 System.
    Wolf T; Gren T; Thieme E; Wibberg D; Zemke T; Pühler A; Kalinowski J
    J Biotechnol; 2016 Aug; 231():122-128. PubMed ID: 27262504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a genome editing technique using the CRISPR/Cas9 system in the industrial filamentous fungus Aspergillus oryzae.
    Katayama T; Tanaka Y; Okabe T; Nakamura H; Fujii W; Kitamoto K; Maruyama J
    Biotechnol Lett; 2016 Apr; 38(4):637-42. PubMed ID: 26687199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods.
    Jo YI; Suresh B; Kim H; Ramakrishna S
    Biochim Biophys Acta; 2015 Dec; 1856(2):234-43. PubMed ID: 26434948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The application of genome editing in studying hearing loss.
    Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
    Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRISPR/Cas9: An RNA-guided highly precise synthetic tool for plant genome editing.
    Demirci Y; Zhang B; Unver T
    J Cell Physiol; 2018 Mar; 233(3):1844-1859. PubMed ID: 28430356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of CRISPR/Cas9 genome editing to the study and treatment of disease.
    Pellagatti A; Dolatshad H; Valletta S; Boultwood J
    Arch Toxicol; 2015 Jul; 89(7):1023-34. PubMed ID: 25827103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The application of somatic CRISPR-Cas9 to conditional genome editing in Caenorhabditis elegans.
    Li W; Ou G
    Genesis; 2016 Apr; 54(4):170-81. PubMed ID: 26934570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR/Cas9 Platforms for Genome Editing in Plants: Developments and Applications.
    Ma X; Zhu Q; Chen Y; Liu YG
    Mol Plant; 2016 Jul; 9(7):961-74. PubMed ID: 27108381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro CRISPR-Cas9-mediated efficient Ad5 vector modification.
    Tang L; Gong M; Zhang P
    Biochem Biophys Res Commun; 2016 May; 474(2):395-399. PubMed ID: 27125457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilization of the CRISPR/Cas9 system for the efficient production of mutant mice using crRNA/tracrRNA with Cas9 nickase and FokI-dCas9.
    Terao M; Tamano M; Hara S; Kato T; Kinoshita M; Takada S
    Exp Anim; 2016 Jul; 65(3):275-83. PubMed ID: 26972821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma.
    Liu T; Shen JK; Li Z; Choy E; Hornicek FJ; Duan Z
    Cancer Lett; 2016 Apr; 373(1):109-118. PubMed ID: 26806808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ji Luo Elucidates the CRISPR Gene Editing Technology, and How It May Affect Cancer Therapy in the Future.
    Luo J
    Oncology (Williston Park); 2016 Oct; 30(10):879. PubMed ID: 27753053
    [No Abstract]   [Full Text] [Related]  

  • 37. Applying CRISPR-Cas9 tools to identify and characterize transcriptional enhancers.
    Lopes R; Korkmaz G; Agami R
    Nat Rev Mol Cell Biol; 2016 Sep; 17(9):597-604. PubMed ID: 27381243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Class 2 CRISPR-Cas RNA-guided endonucleases: Swiss Army knives of genome editing.
    Stella S; Alcón P; Montoya G
    Nat Struct Mol Biol; 2017 Nov; 24(11):882-892. PubMed ID: 29035385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Anti-CRISPR Story: A Battle for Survival.
    Maxwell KL
    Mol Cell; 2017 Oct; 68(1):8-14. PubMed ID: 28985512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CRISPR/Cas9: the gold standard of genome editing?
    Gleeson A; Sawyer A
    Biotechniques; 2018 Jun; 64(6):239-243. PubMed ID: 29939089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.